Cytokinetics Incorporated (NASDAQ:CYTK) : The money flow analysis of Cytokinetics Incorporated (NASDAQ:CYTK) indicates a $0.29 million of outflow was on downticks, whereas, the investors on Wednesday gobbled up stocks worth $0.4 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.36 and so was the total money flow at $0.11 million. The bulls lapped up $0.01 million worth of block trades on upticks. The money flow was $0.01 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Cytokinetics Incorporated (NASDAQ:CYTK), pushing it down by -0.97% for the day. The stock slid $0.09 and traded at $9.18 during the day. Nonetheless, the stock is 1.55% over the previous weeks close.
In an insider trading activity, Gage L Patrick, director of Cytokinetics Inc, executed a transaction worth $6,950 on August 31, 2015. A total of 1,000 shares were purchased at an average price of $6.95. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered. Currently the company Insiders own 5.1% of Cytokinetics Incorporated shares according to the proxy statements. Institutional Investors own 67.75% of Cytokinetics Incorporated shares.
The company shares have rallied 42.18% from its 1 Year high price. On Dec 3, 2015, the shares registered one year high at $13.18 and the one year low was seen on Jul 8, 2015. The 50-Day Moving Average price is $8.28 and the 200 Day Moving Average price is recorded at $8.04. Cytokinetics Incorporated (NASDAQ:CYTK): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $9.40 and $9.13 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $9.62. The buying momentum continued till the end and the stock did not give up its gains. It closed at $9.41, notching a gain of 1.51% for the day. The total traded volume was 567,492 . The stock had closed at $9.27 on the previous day.
Cytokinetics, Incorporated is a clinical stage biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Companys drug candidates that are in clinical development are its skeletal muscle activators tirasemtiv and CK-2127107 and its cardiac muscle activator omecamtiv mecarbil. Tirasemtiv and CK-2127107 are structurally distinct and selective small molecules that activate the fast skeletal muscle troponin complex in the sarcomere by increasing its sensitivity to calcium, leading to an increase in skeletal muscle contractility. COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure) is a Phase II clinical trial designed to assess the pharmacokinetics and tolerability of omecamtiv mecarbil dosed orally in patients with heart failure and left ventricular systolic dysfunction.